Amit Singal, MD: Role of Biomarkers in HCC Risk Stratification, Screening
A discussion on the role of PLSec-AFP for HCC risk stratification in patients with cirrhosis and future screening implementations.
Safety Profile of Ustekinumab Favorable in Patients with IBD, History of BIologic Failure
Rates per 100 person-years for adverse events, infections, and major adverse cardiac events were similar between placebo and ustekinumab through up to 5 years.
Aasma Shaukat, MD, MPH: Better Detection on Colonoscopies
The age of screening for colon cancer has decreased in recent years.
Marla C. Dubinsky, MD: The Next Revolution for IBD Treatments
Dr. Dubinsky said new IL-23 treatments could enable precision medicine in the future for IBD.
Yen-I Chen, MD: EUS-CDL Comparable to ERCP-M in ELEMENT Trial
The findings show EUS-CDL is more efficient than ERCP-M with comparable short-term effectiveness and safety.
Multiple Risk Factors Increase Risk for VTE After Surgery for IBD
Data show the presence of five and six risk factors increased the risk of VTE exponentially to 10.9% and 25%, respectively
Dupilumab Continues to Show Benefit in Treating EoE
The treatment recently became the first ever FDA-approved medication for EoE.
CP101 Prevented Recurrence of C Difficile Infection in PRISM-EXT Trial
Data show the proportion of individuals with sustained clinical cure through Week 8 was 80.3% with CP101 treatment.
Raseen Tariq, MBBS: FMT for Refractory Host Versus Graft Disease
Initial studies have shown a 73% efficacy for FMT in treating patients with HVGD.
Lack of Association Observed Between BMI and Mortality Among C Difficile Hospitalizations
BMI did not have an association with increased risk for death in any BMI category, according to study investigators.
Miguel Regueiro, MD: Safety Data on Ozanimod for Ulcerative Colitis
A look into the efficacy of ozanimod in patients with UC and the potential risk for cardiovascular events.
SER-109 Results in Increase in Microbe-Producing Metabolites
The live microbiota therapeutic has shown promise in treating patients with recurrent CDI.
Taha Qazi, MD: Male Sexual Dysfunction Following Ulcerative Colitis Surgery
Patients who have IPAA are more than twice as likely to suffer from male sexual dysfunction.
TNF-Antagonist Therapy Linked to Better Outcomes for Post-Operative Crohn’s Disease
Patients treated with TNF- antagonists had a higher deep remission rate compared to patients treated with ustekinumab.
DDW Research Shows No Efficacy for Vedolizumab in Treating NAFLD
Patients with IBD are often at an increased risk of developing NAFLD.
Bariatric Surgery Linked to Improved Outcomes After Myocardial Infarction
New data from DDW 2022 show inpatient mortality rates were lower in patients with history of bariatric surgery.
Ken Blount, PhD: Effect of RBX2660 on Microbiome and Bile Acid Composition
Dr. Blount discusses the DDW 2022 poster of distinction on the investigational live biotherapeutic.
Long-Term Assessments Needed to Evaluate Impact of Accelerated Aging on EoE Progression
Post-treatment, data show molecular age remained significantly greater than chronological age at a median difference of 18.6 years.
Ustekinumab, Ozanimod Have Comparable Profiles for Ulcerative Colitis
The data presented at DDW show similar safety and efficacy for the 2 treatments.
RBX2660 Reduces Risk of CDI Recurrence at Week 8
Recurrence commonly occurred during the first 2 weeks regardless of treatment.
Acid Suppression Results in a Decrease in Mortality for GERD Patients Following Lung Transplantation
Both post-transplant PPI and histamine-2 receptor antagonist use were independently associated with reduced risk of 1-year mortality.
Higher Adherence to DASH Diet Linked to Stronger Protection Against NAFLD Risk
DASH diet was inversely associated with NAFLD risk, independent of BMI changes.
Ribavirin Not Effective, Safe for Genotype 3 HCV
The treatment did not improve sustained virologic response but did increase the rate of treatment-related adverse events.
Anti-TNF, Ustekinumab Have Similar Efficacies Against Crohn’s Disease
There remains a need for longer-term observational studies comparing the 2 treatments.
COVID-19 Pandemic Response the Blueprint for Reducing C Difficile Impact
Multiple studies have found a decrease in CDI rates during the COVID-19 pandemic in comparison to previous years.
David M. Poppers, MD: Early Detection for Esophageal Cancer
Esophageal cancer has a low survival rate largely due to advanced stage diagnosis.
Ustekinumab Effective Treating Extra-Intestinal Manifestations of Crohn's Disease
Nearly two-thirds of patients had improved or resolved EIM after ustekinumab treatment.
Brian E. Lacy, MD, PhD: IBS-C Symptoms During COVID-19
A large proportion of IBS-C patients did not seek health care during the COVID-19 pandemic despite symptoms.
Sheldon Sloan, MD: The Promise of Etrasimod at DDW
Arena Pharmaceuticals expects to move forward with later phase clinical trials testing etrasimod.
Christopher V. Almario, MD: Treatment and Prevalence of Opioid-Induced Constipation
Patients with opioid-induced constipation had more frequent, painful constipation symptoms, compared to those with chronic idiopathic constipation.
